(Q33732489)

English

Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

Jennifer A Kanakry

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Yvette L Kasamon

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Javier Bolaños-Meade

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Ivan M Borrello

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Robert A Brodsky

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Ephraim J Fuchs

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Nilanjan Ghosh

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Douglas E Gladstone

8

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Christopher D Gocke

9

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Carol Ann Huff

10

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Christopher G Kanakry

11

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Leo Luznik

12

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

William Matsui

13

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Huzefa J Mogri

14

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Lode J Swinnen

15

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Heather J Symons

16

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Richard J Jones

17

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Richard F Ambinder

18

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

publication date

18 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Biology of Blood and Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1514-1517

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4051232

21 June 2018

Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4051232

21 June 2018

Gastritis Associated with Epstein-Barr Virus Infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4051232

21 June 2018

High-dose cyclophosphamide for graft-versus-host disease prevention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4051232

21 June 2018

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4051232

21 June 2018

Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4051232

21 June 2018

Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4051232

21 June 2018

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4051232

21 June 2018

Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4051232

21 June 2018

Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4051232

21 June 2018

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4051232

21 June 2018

Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4051232

30 October 2018

Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4051232

30 October 2018

The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4051232

30 October 2018

T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantati

1 reference

https://pubmed.ncbi.nlm.nih.gov/23871780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prompt versus preemptive intervention for EBV lymphoproliferative disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23871780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Depletion of EBV-infected cells in donor marrow by counterflow elutriation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23871780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23871780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free sur

1 reference

https://pubmed.ncbi.nlm.nih.gov/23871780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23871780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Haploidentical bone marrow transplants for haematological malignancies using non-myeloablative conditioning therapy and post-transplant immunosuppression with cyclophosphamide: results from a single Australian centre

1 reference

https://pubmed.ncbi.nlm.nih.gov/23871780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.BBMT.2013.07.013

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33732489&oldid=1946722752"